DETAILED ACTION
1. The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
2. Applicant's amendment and remarks filed on 08/07/2026 are acknowledged.
Claims 43-53 and 66-68 are pending.
3. Applicant’s election without traverse of the invention of Group I in the reply filed on 08/07/2026 is acknowledged. All presently pending claims read on the elected invention.
4. The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION. —The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
5. Claims 43-53 and 66-68 are rejected under 35 U.S.C. 112(b) as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor regards as the invention.
(i) Claims 43 and 44 are indefinite in the recitation of “levels (cell counts),” because it is unclear whether the phrase in parentheses constitutes a claim limitation.
(ii) Claim 43 is indefinite in the recitation of “control or reference,” because neither control nor reference level is defined.
(iii) Claim 44 is indefinite in the recitation of calculating the control or reference “using” the specified levels, because it is unknown how the levels are “used” or how the calculation is performed.
(iv) Claim 48 is indefinite in the recitation of the phrase “wherein the HLA-DR+CCR7+ B cells are further screened based upon expression of CD38 and CD27,” because the meaning of the phrase is unknown. At least the following aspects of the phrase are unclear: the relationship between the process of “screening” and the expression of the markers, i.e. how is the screening “based upon” the expression; the aspects of expression being screened for, i.e. the level or presence vs absence, transcript vs protein; the outcome of performing the screening, i.e. isolated cells, numeric value, etc.
(v) Claims 44-53 and 66-68 are indefinite, because they encompass the indefinite limitations of the claim(s) on which they depend.
In view of the above, a person of ordinary skill in the art cannot unequivocally interpret the metes and bounds of the claims so as to understand how to avoid infringement. Applicant is reminded that any amendment must point to a basis in the specification so as not to add New Matter. See MPEP 714.02 and 2163.06.
6. The following is noted regarding novelty of the claimed invention:
Applicant's claim for domestic priority under 35 U.S.C. 119(e) is acknowledged. It is noted that the Examiner was unable to identify adequate support under 35 U.S.C. 112 for presently pending claims in provisional application USSN 63/196,676 upon which priority is claimed. Consequently, presently pending claims have been accorded the priority of the filing date of PCT/US2022/032010, i.e. 06/02/2022. Should Applicant disagree with the above Examiner’s determination, it is incumbent upon Applicant to provide a showing that specifically supports the indicated claim limitations.
The presently claimed invention is described in the following publication (cited on IDS):
Padrón et al. Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial. Nature Medicine (June 2022), Vol 28, p. 1167–1177.
According to Nature website, accessed on 10/13/2026 at https://www.nature.com/articles/s41591-022-01829-9 (a copy of the first page is cited or record as “Padron 2022 Title Page” and attached hereto), the above document was published on 06/03/2022, i.e. one day later than the priority date accorded to instant claims. As such, Padrón et al. (2022) does not constitute prior art relative to presently claimed invention.
7. The following prior art and post-filing-date documents are cited of record as characterizing the state of the art:
US 20110104671, e.g. [0013];
US 20150037346, e.g. claim 17;
US 20230174658, e.g. [0072].
Beatty et al. (2011) CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science; 331:1612-1616.
McVey et al. (2025) Facts and Hopes of CD40 Agonists in Cancer Immunotherapy. Clin Cancer Res; 31: 2079–2087.
Salomon et al. (2022) Next Generation CD40 Agonistic Antibodies for Cancer Immunotherapy. Front. Immunol. 13:940674, p. 1-7.
Vonderheide R.H. (2020) CD40 Agonist Antibodies in Cancer Immunotherapy. Annu. Rev. Med. 71: 47–58.
Wattenberg et al. (2021) Systemic inflammation is a determinant of outcomes of CD40 agonist-based therapy in pancreatic cancer patients. JCI Insight; 6(5): e145389, p. 1-15.
8. Conclusion: no claim is allowed.
9. Any inquiry concerning this communication or earlier communications from the examiner should be directed to ILIA I OUSPENSKI whose telephone number is (571)272-2920. The examiner can normally be reached 9 AM - 5:30 PM.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Julie Wu can be reached at 571-272-5205. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/ILIA I OUSPENSKI/ Primary Examiner, Art Unit 1644